Skip to main content
Vertex's cystic fibrosis drug gets expanded indication

Vertex Pharmaceuticals' Kalydeco, or ivacaftor, has been approved by the FDA to cover 23 new disease-causing mutations in patients with cystic fibrosis based on data from an in-vitro cell study. The updated label indicates Kalydeco as a treatment for patients at least 2 years old with any of 33 mutations of the CF transmembrane conductance regulator gene who are responsive to the drug.

Full Story: